WO1996038450A1 - Cephalosporines - Google Patents
Cephalosporines Download PDFInfo
- Publication number
- WO1996038450A1 WO1996038450A1 PCT/US1996/008928 US9608928W WO9638450A1 WO 1996038450 A1 WO1996038450 A1 WO 1996038450A1 US 9608928 W US9608928 W US 9608928W WO 9638450 A1 WO9638450 A1 WO 9638450A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- group
- alkyl
- compound
- cephem
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- -NR 4 R 5 ' and Z is selected from the group consisting of -CH 2 (X) m -, -C(NOR 6 )-, -CH(OR 7 )-, -C(CHC0 2 R 8 )- and -CH(NR 9 R 10 ) - ;
- n is selected from the group consisting of 0 and 1;
- R 2 is selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heterocycle, aralkyl, heteroaralkyl, and trialkylsilyl;
- R 11 is selected from the group consisting of H, halogen, alkyl, hydroxyl, amino, cyano, hydroxyalkyl, carboxamidoalkyl, optionally substituted aminoalkyl or quaternary ammonium alkyl, and quaternary heteroaryliumalkyl;
- R 17 is H or alkyl.
- Preferred compounds include those compounds wherein R 11
- the present invention includes methods for treating a bacterial infection in a mammal arising from bacteria resistant to ⁇ -lactam antibiotics comprising administering to a mammal suffering from such an infection a therapeutically effective amount of a compound of Structure II.
- the present invention provides methods for using a thiolate nucleophile of the structure
- heterocycle denotes a chain of carbon and at least one non-carbon atoms which together form one or more aromatic or non-aromatic rings having preferrably between about 6-14 atoms, such as, e.g. , furyl, thienyl, imidazolyl, indolyl, pyridinyl, thiadiazolyl, thiazolyl, piperazinyl, dibenzfuranyl, dibenzthienyl . These rings may be optionally substituted with one or more functional groups which are attached commonly to such rings, such as, e.g..
- heterotricycle denotes an aromatic heterocyclic substituent as defined above which comprises three aromatic rings.
- heterocyclecarbonyl denotes the group
- ⁇ -lactam resistant bacteria refers to bacteria against which a ⁇ -lactam antibiotic has an minimum inhibitory concentration (MIC) greater than 32 mg/ml.
- R 6 is selected from the group consisting of hydrogen, methyl, 2-fluoroethyl, cyclopropylmethyl, allyl, dichloroallyl and cyclopentyl
- R 3 is selected from the group consisting of phenyl, 2-thienyl, 2-furyl, 2-aminothiazol-4-yl, and 2-aminothiadiazol-4-yl;
- R 13 - R 17 are H or lower alkyl .
- R 13 -R 17 are hydrogen.
- a suitable effective dose of the compound of the invention will be in the range of 0.1 to 1000 milligram (mg) per recipient per day, preferably in the range of 1 to 100 mg per day.
- the desired dosage is preferably presented in one, two, three, four or more subdoses administered at appropriate intervals throughout the day. These subdoses can be administered as unit dosage forms, for example, containing 5 to 1000 mg, preferably 10 to 100 mg of active ingredient per unit dosage form.
- the compounds of the invention will be administered in amounts of between about 2.0 mg/kg to 250 mg/kg of patient body weight, between about one to four times per day.
- Disposable sterile l ⁇ L loops were used to inoculate test plates, with each isolate in a designated grid on the agar plate.
- An alternate method of inoculation involved the use of a replica plater, a device with 48 steel pins allowing the simultaneous inoculation of multiple isolates. After the spots had dried, the plates were incubated at 35-36°C for 16-20 hours. Endpoints were assessed as the minimum inhibitory concentration (MIC) of antimicrobial agent.
- MIC minimum inhibitory concentration
- aureus 76 (Meth R )(lac + ) >32 4 4 4 8 2 8
- mice Groups of 5 female Swiss-Webster mice (Simonsen, Gilroy, CA) each are challenged by the intraperitoneal (IP) route with tenfold increments of a bacterial inoculum. This permits calculation of the mean lethal dose (LD 50 ) and the LD 100 .
- mice are challenged IP with an LD 100 titer of bacteria.
- groups of 10 mice each are treated subcutaneously with two-fold increments of the test drug and an antibiotic of known efficacy in mice and humans (i.e., positive control) . Mice are observed for 72h. Those alive at 72h are considered long term survivors.
- the total drug dose in mg/kg that protects 50% of mice in a group from death is termed the mean protective dose (PD 50 ) .
- PD 50 s are similarly determined for several pathogens.
- the quantitative endpoints for the new drug are then compared with those obtained with reference antibiotics.
- Six ten-fold dilutions of inoculum suspended in 0.5 mL of sterilized 7% hog gastric mucin (Sigma) are injected IP in groups of 5 mice each. A control group of 5 mice receive mucin alone. Mice are observed for 72h. Those alive at 72h are considered long term survivors.
- the mean lethal dose (LD 50 ) and 100% lethal dose (LD 100 ) are determined by the probit test.
- mice are challenged IP with bacterial titers that will afford an LD 100 for the test strain.
- SC subcutaneous route
- Drug doses can range from 0.01 to 512 mg/kg. If the drug is poorly soluble, Tween 20 or propylene glycol will be employed to solubilize the drug. Animals are observed for 72h.
- the 50% protective dose (PD 50 ) is calculated in mg/kg by the probit method.
- the PD 50 is the same as the 50% effective dose (ED 50 ) and the 50% curative dose (CD 50 ) .
- Samples of blood from the hearts of all animals that die and from half the mice that survive are cultured on brain-heart infusion agar. Animals that received a protective dosage of the test drug will be alive at 72h, although they may appear moderately ill to very ill during the observation period. Infected, placebo-treated control mice and those receiving non-effective i.e. lower dosages of the test drug will demonstrate a high rate of mortality. Most of these mice will die within 6 to 48 h. Those alive at 72h will be considered long term survivors.
- the mixture was diluted with dichloromethane (20 mL) , and was washed with 5% aqueous sodium bicarbonate solution (20 mL) .
- the organic layer was dried with sodium sulfate, and the solvent was removed with a rotary evaporator.
- the residue was subjected to flash chromatography on silica gel (33% to 50% ethyl acetate/hexane) to afford 300 mg (45%) of the title compound.
- the mixture was diluted with dichloromethane (20 mL) , and was washed with 5% aqueous sodium bicarbonate solution (20 mL) .
- the organic layer was dried with sodium sulfate, and the solvent was removed with a rotary evaporator.
- the residue was subjected to flash chromatography on silica gel (33% to 50% ethyl acetate/hexane) to afford 300 mg (50%) of the title compound.
- Example 33 The procedure of Example 33 is employed, except (71?) -7- [ (phenylacetyl) amino] -3- (4-biphenylthio) -3-cephem-4-c arboxylate, benzhydryl ester is used.
- Example 33 The procedure of Example 33 is employed, except (71?) -7- [ (phenylacetyl) amino] -3- [4- (2-imidazolyl) phenylthio] - 3
- Example 33 The procedure of Example 33 is employed, except (71?) -7- [ (phenylacetyl) amino] -3- [3-bromo-4- (phenyl) phenylthio ] -3-cephem-4-carboxylate, benzhydryl ester is used.
- Example 52 Using substantially the same procedure as in Example 51, the items of the following Examples 52 - 82 can similarly be prepared.
- Example 51 The procedure of Example 51 is employed, but the reactants are 2- (iodophenythio) acetic acid and (71?) -7-amino-3- [2-iodophenylthio] -3-cephem-4-carboxylate, 4-methoxybenzyl ester.
- Example 51 The procedure of Example 51 is employed, but the reactants are 2- (iodophenythio) acetic acid and (71?) -7-amino-3- (biphenylthio) -3-cephem-4-carboxylate, 4-methoxybenzyl ester.
- Example 51 The procedure of Example 51 is employed, but the reactants are 2- (2-furyl) -2- (syn-methoxyimino) acetic acid and
- Example 51 The procedure of Example 51 is employed, but the reactants are 2- (2-furyl) -2- (syn-methoxyimino) acetic acid and
- Example 51 The procedure of Example 51 is employed, but the reactants are cyanoacetic acid and
- EXAMPLE 82 (71?) -7- [(a- [D-4-Ethyl-2,3-dioxo-l-piperazinecarboxamido] -a-p henylacetyl)amino] -3- [dibenzofuran-3-ylthio] -3-cephem-4-carb oxylate, 4-methoxybenzyl ester
- Example 83 Under substantially the same procedure as in Example 83, the items of the following Examples 84 - 88 are similarly prepared.
- EXAMPLE 88 (71?) -7- [ (a- [D-4-Ethyl-2,3-dioxo-l-piperazinecarboxamido] -a-p henylacetyl)amino] -3- [4- (chloromethyl)phenylthio] -3-cephem-4 -carboxylate, 4-methoxybenzyl ester
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59855/96A AU5985596A (en) | 1995-05-31 | 1996-05-29 | Cephalosporin antibiotics |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/455,969 US5698547A (en) | 1994-04-01 | 1995-05-31 | Cephalosporin antibiotics |
US08/455,969 | 1995-05-31 | ||
US08/457,673 | 1995-06-01 | ||
US08/457,673 US5688786A (en) | 1994-04-01 | 1995-06-01 | β-lactam antibiotics |
US60/005,426 | 1995-10-10 | ||
US542695P | 1995-10-12 | 1995-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996038450A1 true WO1996038450A1 (fr) | 1996-12-05 |
Family
ID=27357883
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008928 WO1996038450A1 (fr) | 1995-05-31 | 1996-05-29 | Cephalosporines |
PCT/US1996/008141 WO1996038448A1 (fr) | 1995-05-31 | 1996-05-31 | ANTIBIOTIQUES DU TYPE β-LACTAME |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008141 WO1996038448A1 (fr) | 1995-05-31 | 1996-05-31 | ANTIBIOTIQUES DU TYPE β-LACTAME |
Country Status (2)
Country | Link |
---|---|
AU (2) | AU5985596A (fr) |
WO (2) | WO1996038450A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021623A1 (fr) * | 1999-09-22 | 2001-03-29 | Essential Therapeutics, Inc. | Antibiotiques a l'acide 7-acylamino-3-heteroarylthio-3-cephem carboxylique et promedicaments de ces derniers |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271222B1 (en) * | 1998-05-28 | 2001-08-07 | Merck & Co., Inc. | Penem antibacterial compounds, compositions and methods of treatment |
CN1219512C (zh) | 2000-10-19 | 2005-09-21 | 阿姆拉有限公司 | 含奥沙培南-3-羧酸的药物组合物 |
EP1199077A1 (fr) * | 2000-10-19 | 2002-04-24 | Amura Limited | Compositions pharmaceutiques contenant des acides oxapénème-carboxyliques stabilisées par lyophilisation avec des excipients pharmaceutiques |
CN112321606B (zh) * | 2020-11-04 | 2022-05-17 | 福安药业集团重庆博圣制药有限公司 | 头孢唑肟钠及其中间体的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992377A (en) * | 1974-12-13 | 1976-11-16 | Eli Lilly And Company | 3-Thio-substituted cephalosporin antibiotics |
CH605998A5 (en) * | 1974-08-30 | 1978-10-13 | Ciba Geigy Ag | 3-Thio-7-amino-3- and-2-cephem-4-carboxylic acids |
CH605999A5 (en) * | 1974-08-30 | 1978-10-13 | Ciba Geigy Ag | 3-Thio-7-amino-3- and-2-cephem-4-carboxylic acids |
US4123528A (en) * | 1975-11-21 | 1978-10-31 | Merck & Co., Inc. | 3-(Substituted thio) cephalosporins, derivatives and nuclear analogues thereof |
US5162521A (en) * | 1991-06-06 | 1992-11-10 | Bristol-Myers Squibb Company | Processes for making cephems from allenylazetidinone derivatives |
WO1995026966A1 (fr) * | 1994-04-01 | 1995-10-12 | Microcide Pharmaceuticals, Inc. | Cephalosporines antibiotiques |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS609515B2 (ja) * | 1976-08-09 | 1985-03-11 | 塩野義製薬株式会社 | 3′−ノルオキサセファロスポリン類 |
US4168314A (en) * | 1977-11-17 | 1979-09-18 | Merck & Co., Inc. | 6-(1'-Hydroxyethyl)-2-aminoethylthio-pen-2-em-3-carboxylic acid |
DE2966497D1 (en) * | 1978-10-24 | 1984-01-26 | Merck & Co Inc | 6-, 1- and 2-substituted-1-carbapen-2-em-3-carboxylic acids, processes for the preparation of such compounds and pharmaceutical composition comprising such compounds |
EP0011173B1 (fr) * | 1978-11-01 | 1983-05-11 | Sanraku-Ocean Co., Ltd. | Procédé pour la production de composés antibiotiques bêta-lactame |
EP0074599A1 (fr) * | 1981-09-09 | 1983-03-23 | Takeda Chemical Industries, Ltd. | Dérivés de 5,6-cis-carbapénème, leurs préparation et utilisation |
US4640915A (en) * | 1982-03-29 | 1987-02-03 | Fujisawa Pharmaceutical Co., Ltd. | 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives |
EP0113101A1 (fr) * | 1982-12-30 | 1984-07-11 | Merck & Co. Inc. | Esters d'acides 6-(1-hydroxyéthyl)-2-SR8-1-méthyl-1-carbadéthiapén-2-ème-3-carboxyliques |
JPS60174787A (ja) * | 1984-02-21 | 1985-09-09 | Kyowa Hakko Kogyo Co Ltd | 3位置換カルバセフエム化合物 |
JPS60202886A (ja) * | 1984-03-27 | 1985-10-14 | Sankyo Co Ltd | 1―置換カルバペネム―3―カルボン酸誘導体 |
US4806637A (en) * | 1986-03-17 | 1989-02-21 | Schering Corporation | 6-(Hydroxyethyl)-2-(heterocyclylthio)-penem-3-carboxylates |
ES2051700T3 (es) * | 1986-03-27 | 1994-07-01 | Sumitomo Pharma | Un proceso para la preparacion de un compuesto beta-lactama. |
DE3920743A1 (de) * | 1989-06-24 | 1991-01-10 | Bayer Ag | 2-isocepheme und 2-oxa-isocepheme, verfahren zu ihrer herstellung und ihre verwendung als und in arzneimitteln |
AU636913B2 (en) * | 1989-10-11 | 1993-05-13 | Takeda Chemical Industries Ltd. | Tricyclic carbapenem compounds |
US5077287A (en) * | 1991-01-18 | 1991-12-31 | Eli Lilly And Company | 3-thiazolylthio carbacephem antibacterial agents |
GB9104769D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
GB9104838D0 (en) * | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
EP0507313A1 (fr) * | 1991-04-05 | 1992-10-07 | Takeda Chemical Industries, Ltd. | Composés polycycliques de carbapénèmes, leur préparation et leur utilisation |
US5587474A (en) * | 1992-06-18 | 1996-12-24 | Tanabe Seiyaku Co., Ltd. | Method for removing the protecting group for carboxyl group |
-
1996
- 1996-05-29 AU AU59855/96A patent/AU5985596A/en not_active Abandoned
- 1996-05-29 WO PCT/US1996/008928 patent/WO1996038450A1/fr active Application Filing
- 1996-05-31 AU AU59583/96A patent/AU5958396A/en not_active Abandoned
- 1996-05-31 WO PCT/US1996/008141 patent/WO1996038448A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH605998A5 (en) * | 1974-08-30 | 1978-10-13 | Ciba Geigy Ag | 3-Thio-7-amino-3- and-2-cephem-4-carboxylic acids |
CH605999A5 (en) * | 1974-08-30 | 1978-10-13 | Ciba Geigy Ag | 3-Thio-7-amino-3- and-2-cephem-4-carboxylic acids |
US3992377A (en) * | 1974-12-13 | 1976-11-16 | Eli Lilly And Company | 3-Thio-substituted cephalosporin antibiotics |
US4123528A (en) * | 1975-11-21 | 1978-10-31 | Merck & Co., Inc. | 3-(Substituted thio) cephalosporins, derivatives and nuclear analogues thereof |
US5162521A (en) * | 1991-06-06 | 1992-11-10 | Bristol-Myers Squibb Company | Processes for making cephems from allenylazetidinone derivatives |
WO1995026966A1 (fr) * | 1994-04-01 | 1995-10-12 | Microcide Pharmaceuticals, Inc. | Cephalosporines antibiotiques |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021623A1 (fr) * | 1999-09-22 | 2001-03-29 | Essential Therapeutics, Inc. | Antibiotiques a l'acide 7-acylamino-3-heteroarylthio-3-cephem carboxylique et promedicaments de ces derniers |
Also Published As
Publication number | Publication date |
---|---|
AU5985596A (en) | 1996-12-18 |
WO1996038448A1 (fr) | 1996-12-05 |
AU5958396A (en) | 1996-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5604218A (en) | Cephalosporin antibiotics | |
US6057312A (en) | Cephalosporin antibiotics | |
CZ280411B6 (cs) | D-2-Aminoacyl-3-(Z)-propenylcefalosporinové deriváty, způsob jejich přípravy a farmaceutické přípravky, které je obsahují | |
US6025352A (en) | Cephalosporin antibiotics | |
WO1996038450A1 (fr) | Cephalosporines | |
EP0727426A2 (fr) | Dérivés de céphalosporine | |
EP0699681A1 (fr) | Dérivés de céphalosporine | |
US5698547A (en) | Cephalosporin antibiotics | |
US6030965A (en) | Cephalosporin antibiotics | |
EP1059293A1 (fr) | Dérivés d'amino-chlorothiazole | |
LT4193B (en) | Cephalosporin antibiotics | |
NZ500512A (en) | Cephalosporin for treating beta-lactam antibiotic resistant bacteria (such as S. aureus, E. faecium or E. faecalis) or PBP2a-producing bacteria | |
RU2172317C2 (ru) | Производные цефалоспорина, содержащая их антибактериальная композиция, производные 2-аминотиазолов в качестве промежуточных соединений и способ их получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |